As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
BUSINESS
Detailed Data Out for PIII Zolbetuximab Study in 1st-Line Gastric Cancer: Astellas
Astellas Pharma’s first-in-class anti-Claudin 18.2 antibody zolbetuximab in combination with the CAPOX chemotherapy cut the risk of disease progression or death by over 30% versus CAPOX alone in certain treatment-naïve gastric cancer patients, according to the latest data. The company…
To read the full story
Related Article
- FDA Accepts Re-Filing of Astellas’ Gastric Cancer Med for Review
June 3, 2024
- FDA Rejects Astellas’ Gastric Cancer Med over Manufacturing Issues
January 10, 2024
- Astellas’ 1st-in-Class Gastric Cancer Med Bags Priority Review in US
July 7, 2023
- Astellas Files Zolbetuximab for CLDN18.2-Positive Gastric Cancer in Japan
June 12, 2023
- Astellas’s Zolbetuximab Makes Marks in Another PIII Gastric Cancer Study
December 19, 2022
- Astellas’s Zolbetuximab Hits Goals in PIII Gastric Cancer Trial
November 18, 2022
BUSINESS
- Nxera to No Longer Invest in Non-Priority Assets, Shifts 80% of Pipeline to Obesity and Metabolic Areas
November 19, 2025
- Chugai to Absorb Renalys Pharma in Late December
November 19, 2025
- Nxera Unveils Restructuring Plan to Return to Profit, 15% Job Cuts in Japan and UK
November 18, 2025
- Vital KSK to Repurpose Shield’s Iron Deficiency Drug for PAH in Japan
November 18, 2025
- Lundbeck Files Anti-CGRP Antibody Eptinezumab in Japan
November 18, 2025
Japan is set to tighten reimbursement rules for regenerative medicine products granted conditional, time-limited approval, with Central Social Insurance Medical…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…